Needham & Company LLC Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price

Key Points

• Needham & Company LLC raised its price target on Cytokinetics from $85 to $102 and keeps a "buy" rating, implying about a 32.5% upside; multiple other analysts have also lifted targets and the MarketBeat consensus target is $92.10 ("Moderate Buy").
• Positive Phase 3 ACACIA‑HCM results for aficamten drove a stock rally — shares traded up 16.6% to $76.99 on heavy volume as media coverage and analyst/institutional buying amplified the move.
• The company remains unprofitable with recent EPS misses and a negative FY consensus (avg. -6.31 EPS), while insiders have executed planned sales (181,476 shares sold in the last three months), leaving insider ownership around 2.6%.

Cytokinetics (NASDAQ:CYTK - Get Free Report) had its target price boosted by Needham & Company LLC from $85.00 to $102.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Needham & Company LLC's target price indicates a potential upside of 32.49% from the company's current price.

Several other equities analysts also recently weighed in on the company. Jefferies Financial Group reissued a "buy" rating and set a $90.00 price target on shares of Cytokinetics in a research report on Friday, January 9th. Robert W. Baird set a $84.00 price objective on Cytokinetics in a research note on Tuesday, March 10th. Barclays boosted their target price on shares of Cytokinetics from $87.00 to $95.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. Royal Bank Of Canada upped their target price on shares of Cytokinetics from $95.00 to $101.00 and gave the company an "outperform" rating in a report on Friday, February 20th. Finally, B. Riley Financial raised their price target on shares of Cytokinetics from $90.00 to $108.00 and gave the stock a "buy" rating in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $92.10.

Cytokinetics Trading Up 16.6%

Shares of NASDAQ:CYTK traded up $10.94 during midday trading on Tuesday, hitting $76.99. 15,758,634 shares of the stock were exchanged, compared to its average volume of 2,022,424. Cytokinetics has a twelve month low of $29.31 and a twelve month high of $80.20. The company has a 50 day moving average price of $63.81 and a 200-day moving average price of $63.53. The stock has a market cap of $9.56 billion, a P/E ratio of -11.79 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. During the same period in the prior year, the firm posted ($1.26) EPS. The company's revenue was up 4.9% compared to the same quarter last year. On average, equities research analysts expect that Cytokinetics will post -6.31 earnings per share for the current year.

Insider Activity at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 3,500 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $65.69, for a total transaction of $229,915.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares of the company's stock, valued at $10,109,822.38. The trade was a 2.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,857 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $65.00, for a total value of $1,030,705.00. Following the completion of the transaction, the executive vice president directly owned 58,555 shares in the company, valued at $3,806,075. This trade represents a 21.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 181,476 shares of company stock worth $11,368,524. 2.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Calamos Advisors LLC acquired a new position in shares of Cytokinetics in the 1st quarter valued at about $1,425,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Cytokinetics during the first quarter valued at approximately $8,928,000. Emerald Advisers LLC purchased a new position in shares of Cytokinetics in the first quarter valued at $13,104,000. State of Michigan Retirement System boosted its stake in shares of Cytokinetics by 1.7% in the first quarter. State of Michigan Retirement System now owns 29,400 shares of the biopharmaceutical company's stock valued at $1,938,000 after purchasing an additional 500 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Cytokinetics by 11.9% during the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company's stock valued at $72,072,000 after purchasing an additional 116,593 shares in the last quarter.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Topline Phase 3 success — ACACIA‑HCM met both dual primary endpoints (KCCQ and exercise capacity) with supportive secondary data, providing the primary market catalyst behind today’s rally. GlobeNewswire Release
• Positive Sentiment: Broad media confirmation and market reaction — major outlets reported the late‑stage success, boosting credibility and accelerating buying interest. Coverage highlights likely next steps toward regulatory interactions and commercialization planning. Reuters: Late‑stage study
• Positive Sentiment: Analyst / institutional backdrop supports upside — several analysts and institutional investors have been lifting targets and adding positions this year, which magnifies the impact of a positive Phase 3 readout on upside expectations. MarketBeat coverage
• Neutral Sentiment: Insider selling disclosed — EVP Andrew Callos sold 15,857 shares under a pre‑arranged Rule 10b5‑1 plan (transaction executed May 1 at ~$65 per share); sales were disclosed publicly and appear planned rather than reactive. InsiderTrades filing
• Neutral Sentiment: Company hosted/announced a webcast and conference call to discuss topline results — investors should monitor the presentation and Q&A for safety details, subgroup analyses, and next‑step regulatory guidance. GlobeNewswire: Announcement
• Negative Sentiment: Ongoing financial profile and prior earnings misses — the company remains unprofitable with recent quarterly EPS misses and negative FY consensus, which means valuation and path‑to‑profitability will remain key investor considerations even after the clinical win. Earnings preview

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.